Group 1 - The Hong Kong innovative drug sector continues to rise, with the Hang Seng Innovative Drug Index up by 3.0% as of 10:48, and notable gains in stocks such as Innovent Biologics up over 6%, CanSino Biologics and CSPC Pharmaceutical Group up over 5% [1] - The Hang Seng Innovative Drug ETF (159316) has seen a trading volume exceeding 400 million yuan, with net inflows for four consecutive trading days, bringing its latest scale to 1.8 billion yuan [1] - The National Healthcare Security Administration has officially announced the preliminary review list of drugs for the 2025 medical insurance and commercial insurance innovative drug directory, featuring new drugs including the "million-dollar cancer drug" CAR-T products and several "first and only in the world" products [1] Group 2 - CITIC Securities anticipates a significant increase in innovative drug catalyst events in September, and the recent technology switch has alleviated the short-term speculative money previously accumulated in the sector, suggesting that innovative drugs may continue to rise after this adjustment [1] - The Hang Seng Innovative Drug Index has officially adjusted to exclude contract research organizations (CROs), achieving a "100% purity" index that more accurately reflects the overall performance of China's innovative drug companies [1] - Backtesting indicates that since the index's launch on July 10, 2023, the annualized return and Sharpe ratio have improved after excluding CROs, making the Hang Seng Innovative Drug ETF (159316) the only product tracking this index, aiding investors in precisely positioning themselves for opportunities in the innovative drug industry [1]
创新药概念再度走强，恒生创新药ETF（159316）等产品成交活跃，机构称创新药有望继续上行